跳至主要内容
临床试验/CTRI/2019/11/021932
CTRI/2019/11/021932尚未招募不适用

"Pilot and Validation studies of a new malaria and sickle cell diagnostic device."

Hemex Health Inc1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2019年11月11日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
200
试验地点
1
主要终点
Primary endpoint of the study is the accuracy of the Hemex Malaria device

研究概览

简要总结

The purpose of this Study is to compare the performance of a new malaria diagnostic device(Gazelle) with the current malaria diagnostic technologies such as RDT (Rapid Diagnostic Test),microscopy and PCR (Polymerase Chain Reaction). The study rationale is that Hemex Malariadevice (Gazelle) is faster, easier and comparable to (as good as) microscopy and/or has betteraccuracy for malaria parasites than RDTs, regardless of the species. The study enrollsapproximately 200 patients who presents with fever to the clinic and each patient sample will betested with Gazelle and RDT, and then compare with microscopy and PCR.

研究设计

研究类型
Observational

入排标准

年龄范围
5.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Present with uncomplicated malaria (fever),Other symptomatic patients (fever, chills etc.) visiting the clinic/lab for various diagnostic purposes, Informed consent for all fresh or frozen samples will be obtained from the patient or obtained from the parent/guardian in case the patient is a minor.

排除标准

  • Presence of any serious or chronic illness requiring medical attention Informed consent not provided Malaria diagnosis within the last two months Treatment for malaria in last two months.

结局指标

主要结局

Primary endpoint of the study is the accuracy of the Hemex Malaria device

时间窗: 4 weeks

次要结局

  • N/A(N/A)

研究者

申办方类型
Other [Private Company]

研究点 (1)

Loading locations...

相似试验